CRC - California Resources Corp
LONG BEACH, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC) plans to release its third quarter 2026 financial results on Monday, November 2nd after market hours.
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The e
Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE:
Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help eligible patients get screened1-3 SimpleScreen CRC expands screening options for adults age 45 and older, providing another way to help reach people who otherwise may remain unscreened SimpleScreen CRC is covered by Medicare, with no out-of-pocket costs for eligible patients with Medicare Part B ABBOTT PARK, Ill., Sept. 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. commercial launch of SimpleScreen™ CRC, an FDA-approved blood-based colorectal cancer (CRC) screening test for adults age 45 and older who are at average risk for the disease.
California Resources (NYSE: CRC - Get Free Report) and Kinetik (NYSE: KNTK - Get Free Report) are both mid-cap energy companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership. Volatility and Risk California Resources has a beta
Freenome is rated Buy, leveraging FDA-approved SimpleScreen CRC and a $410M cash reserve to target the vast unscreened colorectal market. FRNM's SimpleScreen CRC, now out-licensed to Abbott, offers a patient-friendly, blood-based alternative, with up to $700M in milestone payments and 10% royalties. Upcoming catalysts include the pivotal PROACT LUNG study for SimpleScreen Lung, which could validate the multiomics platform across multiple indications.
CRC plans to sell its non-core Uinta Basin assets for about $90 million, freeing cash to support its California-focused strategy and capital allocation.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Hu
LONG BEACH, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC) today announced the signing of an agreement to divest its Uinta Basin assets to an undisclosed buyer for total cash consideration of approximately $90 million, subject to customary purchase price adjustments.
Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. [url="]announced[/url] that updated data, including overall survival (OS), from
California Resources (CRC) reported earnings 30 days ago. What's next for the stock?
CRC's $63 million Crimson acquisition expands its California pipeline network, boosting transport flexibility while opening potential CO2 infrastructure options.
LONG BEACH, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC) today announced the closing of its approximately $63 million all-cash acquisition of Crimson Midstream Holdings, LLC (“Crimson”) from CorEnergy Infrastructure Trust, Inc. The transaction was approved by the California Public Utilities Commission on August 13, 2026.
LONG BEACH, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC) today announced the publication of its 2025 Sustainability Report Update and 2025 Sustainability Report Summary. The reports highlight CRC's continued progress in responsibly producing energy, expanding Carbon TerraVault's (CTV) carbon management platform and advancing innovative solutions that support California's evolving energy needs.
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lanc
California Resources is cutting costs and improving drilling efficiency, but weaker estimates and market-access uncertainty continue to weigh on shares.
California Resources Corporation is cutting costs and improving well productivity, but a rich valuation and falling 2026 estimates keep the investment case mixed.
California Resources Corporation is adding pipelines, storage and market access after Q2 bottlenecks hurt realizations and raised transport costs.
CRC's revenues surge 50.4% as Berry synergies, drilling gains and midstream expansion support growth despite weaker differentials.
Bank of America Corp DE lifted its holdings in shares of California Resources Corporation (NYSE: CRC) by 57.1% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 585,709 shares of the oil and gas producer's stock after acquiring an additional 212,827